Novo Nordisk Seeks FDA Approval for Higher-Dose Wegovy
Recently, Novo Nordisk A/S (NYSE: NVO) took an important step by submitting its supplemental marketing application to the U.S. Food and Drug Administration (FDA). This application is for a higher dosage of the semaglutide injection, specifically 7.2 mg, aimed at chronic weight management.
The Importance of the Higher Dose
The escalated dose of Wegovy, or semaglutide at 7.2 mg, is currently undergoing evaluation by the European Medicines Agency, as well as other regulatory bodies in various countries. This higher dose has the potential to offer additional benefits, particularly for those struggling with obesity.
Review Timeline
According to Novo Nordisk, the expected timeline for a regulatory decision in the EU is set for the first quarter of 2026. For the FDA review, the process is expedited under the Commissioner's National Priority Voucher (CNPV) program, which could mean a decision within 1 to 2 months after the FDA accepts the filing.
Details of the Application
What does the application consist of? It includes promising results from the STEP UP trial, a 72-week phase 3 superiority study that assessed the safety and efficacy of semaglutide 7.2 mg, comparing it against a placebo and the previously available semaglutide 2.4 mg dosage. Involving 1,407 adults with obesity (individuals with a BMI of 30 kg/m2 or more), the trial focused specifically on individuals without diabetes.
Trial Results and Expectations
Patients who administered semaglutide 7.2 mg saw a mean baseline weight of 249 pounds, achieving an impressive average weight loss of 20.7% over 72 weeks. In contrast, participants using semaglutide 2.4 mg lost 17.5%, while those on placebo lost only 2.4%. Notably, 33.2% of patients taking the higher dose reached a weight loss of 25% or more, compared to just 16.7% with the lower dose and none with a placebo.
Additionally, when accounting for patients who discontinued, 7.2 mg users still reported a significant weight loss of 18.7%, surpassing the 15.6% for those on semaglutide 2.4 mg and 3.9% for placebo. A remarkable 90.7% of patients on the 7.2 mg dose experienced a weight loss of 5% or more, compared to 89.9% with 2.4 mg and just 36.8% for placebo.
Moreover, after the same period, 31.2% of those on the higher dose achieved the notable milestone of a 25% weight loss, in comparison to 15.3% with the lower dose and none on placebo.
Current Market Performance of Novo Nordisk
At the time of the publication, shares of Novo Nordisk experienced a rise of 3.77%, reaching $48.83. This increase highlights the market's positive response to the company's advancements and actions regarding Wegovy.
Frequently Asked Questions
What is Wegovy and how does it work?
Wegovy, containing semaglutide, is an injection used for chronic weight management, working by regulating appetite and caloric intake.
What are the expected benefits of the higher-dose Wegovy?
The higher dose aims to enhance efficacy, potentially leading to greater weight loss results and improved patient outcomes for those struggling with obesity.
When can patients expect FDA approval for this higher dose?
The FDA review process is expected to take between 1 to 2 months following the acceptance of the filing, with results anticipated shortly thereafter.
How does the STEP UP trial data support the application?
The STEP UP trial demonstrated significant weight loss and safety among participants using the 7.2 mg dose, vital data for supporting the FDA application.
What is the market performance of Novo Nordisk like?
Recently, Novo Nordisk saw its shares rise by 3.77%, reflecting positive investor sentiment following advancements in their obesity treatment portfolio.
